一位慢性腎臟病（CKD）病人被開立了 epoetin alfa。下列哪項實驗室數值顯示該藥物達到了治療效果？
A client with chronic kidney disease (CKD) is prescribed epoetin alfa. Which laboratory finding indicates the medication is achieving its therapeutic effect?
- ADecreased blood urea nitrogen (BUN) levels血液尿素氮 (BUN) 數值下降
- BIncreased serum calcium levels血清鈣濃度上升
- CDecreased serum potassium levels血清鉀濃度下降
- DIncreased hematocrit and hemoglobin levels✓ 正解血球容積比及血紅素數值上升
慢性腎臟病病人因為腎臟產生的紅血球生成素（Erythropoietin）不足，常會併發貧血。Epoetin alfa 是一種人工合成的紅血球生成素，其作用是刺激骨髓產生紅血球。因此，評估其療效的最直接指標就是血紅素（Hgb）和血球容積比（Hct）的上升。通常治療目標是將 Hgb 維持在 10-11 g/dL 之間，以避免因血液黏稠度過高增加中風或心肌梗塞的風險。護理師在監測療效時，也必須密切注意病人的血壓，因為此藥物最常見的副作用是高血壓。這題屬於生理適應中的藥物治療評估，重點在於連結藥物機轉與預期臨床結果。其他選項如鉀離子或 BUN 的變化，主要受洗腎或飲食控制影響，與紅血球生成素無直接關聯。
Patients with chronic kidney disease commonly develop anemia because the kidneys produce inadequate erythropoietin. Epoetin alfa is a synthetic erythropoietin that stimulates the bone marrow to produce red blood cells. The most direct indicator of therapeutic effect, therefore, is an increase in hemoglobin (Hgb) and hematocrit (Hct). The usual treatment goal is to maintain Hgb between 10 and 11 g/dL, to avoid the increased risk of stroke or myocardial infarction from excessive blood viscosity. When monitoring efficacy, the nurse must also watch the patient's blood pressure closely, because hypertension is the most common adverse effect of this drug. This item falls under medication therapy evaluation in physiologic adaptation; the focus is on connecting drug mechanism with the expected clinical outcome. Other options, such as changes in potassium or BUN, are affected mainly by dialysis or diet and have no direct relationship to erythropoietin.
在美國，對於 CKD 病人的貧血管理有非常明確的指引，Hgb 超過 11 g/dL 時通常會暫停給藥以防血栓風險；台灣的健保給付標準亦有類似規定，但護理師在臨床衛教時，美國更強調病人自我監測高血壓症狀的教育。